biOasis Technologies Ord Shs BIOAF

Sangamo

[Boomskid]

Bioasis has no immediate interest in Sangamo or any other reported efforts to treat Fabry disease.

If Chiesi (and Protalix) move forward with an xB3 version of PRX-102 for Fabry, the most that Bioasis can gain would be (maybe) a couple of millions in milestone payments in the immediate 2 or 4 years.

Bioasis has already, totally and finally, sold those four LSDs and has nothing else to gain from the deals other than what is likely a low single digit (1% ??) royalty that won't kick in for years.

Each Chiesi LSD was worth an average of $750,000 each, with an average of $34.5 million in milestones, almost entirely payable in late stage clinical trials and upon commercialization if the xB3 drug gets approved in 5 or more years at the earliest.

There are many companies working on Fabry, one of which is Sangamo. Because Bioasis has almost certainly sold xB3 for Fabry to Chiesi, Sangamo's work may affect Chiesi, but it will have no impact on Bioasis.

jd

[prophetoffactz]

Chiesi is a top 50 global pharma company that has targeted Lysosomal Storage as a strategic focus. It is a very patient company directed at the long term. Mol Ther Methods Clin Dev         . 2022 Apr 19;25:370-381.  doi: 10

[Boomskid]

Yes, Chiesi most certainly is patient and does have a long term view, Why, it will be 3 years soon since Chiesi got 4 LSDs from Bioasis for almost nothing. And here we are, no news of what the secret LSDs are, let alone any hint of a developmental milestone, and IND submission or a regulatory milestone. Patient? Or not interested? Waiting for the FDA to approve Protalix's ProCellEx

[prophetoffactz]

"Yes, Chiesi most certainly is patient and does have a long term view..." That's exciting. A top 50 pharma company with a long-term view and strategic focus on Lysosomal Storage and Saltarelli is on Chiesi's xB3 Advisory Board with Mei Mei and Rathjen and Rathjen was upbeat about BTI's partnerships despite the absense of news. Just because there is no news don't mean

[Boomskid]

First of all, I no longer have the faith and admiration you have for Saltarelli, poof. He approved the Midatech sellout and he was going to go with Biodexa. He gets a lot and Bioasis get next to nothing.    He's no friend to shareholders but let's just say that he has poor judgement about deals and leave it at that for the moment.   I'm not surprised about the